Tung T Wynn, MD - UF Health

Dr. Tung Wynn, MD

Claim this profile

University of Florida Hemophilia Treatment Center

Studies Von Willebrand Disease
Studies Hemophilia
6 reported clinical trials
10 drugs studied

Area of expertise

1

Von Willebrand Disease

Tung Wynn, MD has run 3 trials for Von Willebrand Disease.

2

Hemophilia

Tung Wynn, MD has run 3 trials for Hemophilia. Some of their research focus areas include:

FVIII Level positive
FVIII Gene Mutation positive

Affiliated Hospitals

Image of trial facility.

University Of Florida Hemophilia Treatment Center

Image of trial facility.

University Of Florida College Of Medicine

Clinical Trials Tung Wynn, MD is currently running

Image of trial facility.

Natural History Study

for Blood Disorders

In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from well controlled, pivotal studies often cannot be replicated once a therapy has been approved for general use.2,3,4,5 In 2019 alone, the FDA has issued approvals for 24 new therapies for congenital and acquired hematologic conditions.6 In addition, almost 10,000 new studies for hematologic diseases are currently registered on www.clinicaltrials.gov.7 With this increase in potential new therapies possible, it is imperative that clinicians and clinical researchers in the field of non-neoplastic hematology have a uniform, secure, unbiased, and enduring method to collect long-term safety and efficacy data. As emphasized in a recently published review, accurate, uniform and quality national data collection is critical in clinical research, particularly for longitudinal cohort studies covering a lifetime of biologic risk.8

Recruiting

1 award

N/A

1 criteria

Image of trial facility.

rVWF +/− ADVATE

for Von Willebrand Disease

The main aim of the study is to check effectiveness, side effects, and tolerability of vonicog alfa (recombinant von Willebrand factor \[rVWF\]), with or without ADVATE, in the treatment and control of nonsurgical bleeding events in pediatric participants (less than (\<)18 years of age) with severe hereditary von Willebrand disease (VWD). The participants will be treated with vonicog alfa for 12-18 months. Their von Willebrand Disease will be treated by their doctor according to their doctor's usual clinical practice. During the study, participants will be followed up at clinics or over telephone calls.

Recruiting

2 awards

Phase 3

More about Tung Wynn, MD

Clinical Trial Related

5 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Tung Wynn, MD has experience with

  • Various VWF Regimens
  • Antihemophilic Factor (Recombinant)
  • Von Willebrand Factor (Recombinant)
  • ATHN Transcends
  • ITI
  • PEGylated Recombinant Factor VIII

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Tung Wynn, MD specialize in?

Is Tung Wynn, MD currently recruiting for clinical trials?

Are there any treatments that Tung Wynn, MD has studied deeply?

What is the best way to schedule an appointment with Tung Wynn, MD?

What is the office address of Tung Wynn, MD?

Is there any support for travel costs?